News | July 19, 2011

Florbetapir "Imaging to Autopsy" Study Awarded de Leon Prize in Neuroimaging

July 19, 2011 – The study "Use of Florbetapir-PET for Imaging beta-amyloid Pathology," published in the Jan. 19, 2011, issue of the Journal of the American Medical Association, has been selected by the Alzheimer's Association as the winner of the 2011 de Leon Prize in Neuroimaging for the “Best Paper” award in human neuroimaging, in the Senior Scientist category. The award was presented Saturday, July 16, 2011, to Chris Clark, M.D., co-author of the paper and medical director at Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Co., during the Alzheimer's Imaging Consortium (AIC), in Paris, France. The AIC was a preconference to the Alzheimer's Association International Conference 2011 (AAIC 2011), held from July 17-21, 2011.

The paper reported the results of a Phase III "Imaging to Autopsy" study that was designed to determine if florbetapir positron emission tomographic (PET) imaging performed during life predicted the presence or absence of beta-amyloid plaques in the brain at autopsy. The ability to identify and quantify brain beta-amyloid potentially could enable a negative florbetapir-PET scan to rule out amyloid pathology in the brain.

"It is an honor to receive this award as it represents further validation of the importance of the study and recognition of the impact the paper may have on the future of neuroimaging of Alzheimer's disease pathology," said Clark. "Helping to lead this collaborative study was a life-changing event for me and I am pleased to be able to donate the prize earnings back to the Alzheimer's Association to support their efforts."

Florbetapir F18 injection is a molecular PET-imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. Florbetapir F18 was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Florbetapir F18 is neither a screener for asymptomatic patients, nor a standalone diagnostic for Alzheimer's disease.

About the de Leon Prize in Neuroimaging

The de Leon Prize in Neuroimaging is presented by the Neuroimaging Professional Interest Area (NPIA) of ISTAART, the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment.

NPIA awards two prizes annually for the best papers published in any peer-reviewed journal, one in the Senior Scientist category and one in the New Investigator category. Both awards carry unrestricted prizes and are presented during the AIC, a preconference to the AAIC 2011.

The topic of the papers must relate to in-vivo neuroimaging of a neurodegenerative process. The nomination for the "Best Paper" award must be for papers published or in press galley proof, in the period between July 1, 2010 and June 30, 2011.

For more information:



Related Content

News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Overlay Init